Combination therapy shows promise against triple-negative breast cancer
GLP-1 drugs like Ozempic may protect brain health, several studies show
YouTube content can help some people cope with breast cancer diagnosis, Spanish study finds
A study by the University of the Basque Country (UPV/EHU) has identified the most relevant YouTube videos on breast cancer and the concerns of the people who post comments. The study is published in the journal Profesional de la información.
Next-gen weight loss drugs will have fewer side effects than Ozempic, pharma CEO says
Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s designed to work differently from those currently on the market and with the potential for fewer side effects.Read more…
Metabolic-Bariatric Surgery Reduces Pancreatic Cancer Risk
Effect appeared more pronounced among those with type 2 diabetes. Medscape Medical News
This Breast Cancer Ribbon Has a Different Take on Pink. Here’s What It Means
Landmarks around the world will light up in its colors for Breast Cancer Awareness Month.
Breast cancer patient says new type of chemo saved her life: ‘I am thriving’
A medical clinic in Scottsdale, Arizona, offers an alternative, personalized form of chemotherapy designed to target cancer cells without harming healthy cells. A woman says it saved her life.
PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer
(MedPage Today) — The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA-mutated, hormone receptor (HR)-positive/HER2-negative breast…
Increasing amount of breast cancer-specific death due to stage 1, 2 disease
Patients with stage I/II breast cancers have excellent prognosis, but account for more than 60 percent of breast cancer-specific death (BCSD) because of their large absolute volumes, according to a study published online Sept. 30 in the Journal of the National Cancer Institute.
Tirzepatide reduces obstructive sleep apnea symptoms and associated risks
1. In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was found that tirzepatide treatment reduced the occurrence of apneas and hypopneas. 2. Tirzepatide treatment was associated with reduced body weight and sleep apnea-associated cardiovascular risk factors. Evidence Rating Level: 1 (Excellent) Study Rundown: OSA, resulting from
The post Tirzepatide reduces obstructive sleep apnea symptoms and associated risks first appeared on 2 Minute Medicine. Source: 2 Minute Medicine